You searched for "wellbeing"

1747 results found

College comments on the DHSC’s update on GOS sight test fees for England and clinical placement training payments for 2025/2026

This week, the Department of Health and Social Care published details of its confirmed NHS sight test fee and NHS domiciliary fees from 1 April 2025, continuing professional development payments for 2024, and clinical placement training payments from 1 April...

RANZCO Congress 2025

The Royal Australian and New Zealand College of Ophthalmologists Annual Congress 2025

Conference Report: Retina UK 2025

The Retina UK Annual Conference 2025 took place at the Holiday Inn London in London, UK, on 20 September and was hosted both in-person and online. The event included expert speakers, healthcare professionals, and patients with lived experience with retinal...

Management of a giant pigment epithelium detachment with transition from half- to full-dose aflibercept

This case report describes the management of a giant pigment epithelial detachment (PED) in neovascular age-related macular degeneration (nAMD) using half-dose aflibercept. An 80-year-old woman presented with a huge PED (maximum height 1338µm) and multiple risk factors for retinal pigment...

Sheraz Daya awarded prestigious IIRSI gold medal for contribution to ophthalmology

Centre for Sight, the UK’s leading and most trusted centre of excellence for advanced eye care, innovation and life-changing results, is proud to announce that its Founder and Medical Director, Sheraz Daya, has been awarded the prestigious IIRSI Gold Medal...

Prognosis of ocular motor cranial nerve palsies caused by pituitary adenoma and meningioma

The authors present a retrospective cohort study with the aim of comparing recovery rate and time of ocular motor cranial nerve palsies (CNP) caused by pituitary adenoma or meningioma. Cases were identified from a single tertiary referral centre over a...

Comparison of the efficacy of anti-VEGFs agents in nvAMD

This retrospective multicentric study conducted in Israel and Canada, compared the efficacy of bevacizumab, aflibercept 2mg and ranibizumab as first-line treatments for neovascular age-related macular degeneration (nvAMD). Included were treatment-naïve nvAMD eyes receiving ≥12 months of treat-and-extend (T&E) anti-VEGF therapy...

Glaucoma UK appoints Professor Cecilia Fenerty as new Chair of Trustees

Glaucoma UK has appointed Professor Cecilia Fenerty as its new Chair of Trustees following the charity’s Annual General Meeting in March 2026. Professor Fenerty succeeds Professor Anthony King, who stepped down after completing four years as Chair and nine years...

Eye research: where next?

Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...

See sweet to C-suite: Imran Rahman

See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...

A trip up north: Eye News Symposium 2020

New accents, friendly smiles and haggis served with my traditional morning breakfast, I knew at this point that I was a long way from the south of England, where this story begins.

Effective treatment for rare sight-threatening infection

A drug candidate, based on pioneering UCL and Moorfields Eye Hospital research and currently under development by SIFI S.p.A., has been found to be highly effective in treating a rare sight-threatening eye infection in a new international clinical trial.